Skip to main content

NICE

Volume 453: debated on Monday 20 November 2006

To ask the Secretary of State for Health if she will permit the National Institute for Health and Clinical Excellence to negotiate on price with pharmaceutical companies the indicative prices they are given for the purposes of assessing the cost-effectiveness of treatments being subjected to a technology appraisal. (101686)

The Department has no plans to give the National Institute for Health and Clinical Excellence a role in drug price negotiation. The Pharmaceutical Price Regulation Scheme (PPRS) is the means by which the Government seek to achieve a balance between reasonable prices for the national health service and a fair return for the pharmaceutical industry.